T. Rowe Price Associates
TEVA icon

T. Rowe Price Associates’s Teva Pharmaceuticals TEVA Stock Holding History

T. Rowe Price Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1M Sell
634,136
-925,466
-59% -$29.8M ﹤0.01% 1052
2025
Q4 		$48.7M Buy
1,559,602
+1,050,901
+207% +$25.9M 0.01% 823
2025
Q3 		$10.3M Buy
508,701
+47,586
+10% +$836K ﹤0.01% 1220
2025
Q2 		$7.73M Buy
461,115
+55,423
+14% +$894K ﹤0.01% 1169
2025
Q1 		$6.24M Sell
405,692
-1,643,696
-80% -$29.4M ﹤0.01% 1210
2024
Q4 		$45.2M Buy
2,049,388
+1,223,957
+148% +$22.3M 0.01% 787
2024
Q3 		$14.9M Buy
825,431
+571,302
+225% +$10M ﹤0.01% 1057
2024
Q2 		$4.13M Buy
254,129
+52,280
+26% +$805K ﹤0.01% 1282
2024
Q1 		$2.85M Buy
201,849
+36,295
+22% +$458K ﹤0.01% 1412
2023
Q4 		$1.73M Buy
165,554
+14,100
+9% +$132K ﹤0.01% 1610
2023
Q3 		$1.55M Buy
151,454
+11,100
+8% +$103K ﹤0.01% 1580
2023
Q2 		$1.06M Buy
140,354
+3,731
+3% +$30.3K ﹤0.01% 1782
2023
Q1 		$1.21M Buy
136,623
+11,993
+10% +$119K ﹤0.01% 1682
2022
Q4 		$1.14M Buy
124,630
+5,900
+5% +$51.5K ﹤0.01% 1705
2022
Q3 		$959K Sell
118,730
-600,174
-83% -$5.31M ﹤0.01% 1774
2022
Q2 		$5.41M Buy
718,904
+68,189
+10% +$594K ﹤0.01% 1417
2022
Q1 		$6.11M Buy
650,715
+116,033
+22% +$968K ﹤0.01% 1431
2021
Q4 		$4.28M Buy
534,682
+25,852
+5% +$233K ﹤0.01% 1517
2021
Q3 		$4.96M Sell
508,830
-9,000
-2% -$84.3K ﹤0.01% 1510
2021
Q2 		$5.13M Buy
517,830
+407,900
+371% +$4.32M ﹤0.01% 1499
2021
Q1 		$1.27M Buy
109,930
+3,700
+3% +$42.4K ﹤0.01% 1932
2020
Q4 		$1.02M Buy
106,230
+43,500
+69% +$417K ﹤0.01% 1926
2020
Q3 		$565K Hold
62,730
– – ﹤0.01% 2039
2020
Q2 		$773K Buy
62,730
+1,100
+2% +$12.4K ﹤0.01% 1895
2020
Q1 		$553K Buy
61,630
+31,730
+106% +$325K ﹤0.01% 1937
2019
Q4 		$293K Buy
29,900
+6,600
+28% +$58.9K ﹤0.01% 2325
2019
Q3 		$160K Sell
23,300
-9,530,028
-100% -$73M ﹤0.01% 2414
2019
Q2 		$88.2M Buy
9,553,328
+1,593,139
+20% +$19.2M 0.01% 684
2019
Q1 		$125M Buy
7,960,189
+1,116,003
+16% +$19.7M 0.02% 577
2018
Q4 		$106M Buy
6,844,186
+639,968
+10% +$13.1M 0.02% 595
2018
Q3 		$134M Buy
6,204,218
+403,265
+7% +$9.36M 0.02% 589
2018
Q2 		$141M Buy
5,800,953
+2,796,469
+93% +$57M 0.02% 567
2018
Q1 		$51.3M Buy
+3,004,484
New +$58.7M 0.01% 860
2017
Q3 		– Sell
-1,284,800
Closed -$42.7M – 2586
2017
Q2 		$42.7M Sell
1,284,800
-3,493,546
-73% -$108M 0.01% 889
2017
Q1 		$153M Sell
4,778,346
-2,470,483
-34% -$84.3M 0.03% 492
2016
Q4 		$263M Buy
7,248,829
+955,694
+15% +$38.2M 0.05% 361
2016
Q3 		$290M Buy
6,293,135
+157,944
+3% +$8.24M 0.06% 319
2016
Q2 		$308M Sell
6,135,191
-269,555
-4% -$14.4M 0.07% 301
2016
Q1 		$343M Buy
6,404,746
+19,407
+0.3% +$1.14M 0.07% 289
2015
Q4 		$419M Sell
6,385,339
-671,571
-10% -$41.5M 0.09% 245
2015
Q3 		$398M Sell
7,056,910
-469,554
-6% -$30.4M 0.09% 251
2015
Q2 		$445M Buy
7,526,464
+114,904
+2% +$7.09M 0.09% 245
2015
Q1 		$462M Buy
7,411,560
+1,326,854
+22% +$77.1M 0.1% 251
2014
Q4 		$350M Buy
6,084,706
+755,668
+14% +$42.1M 0.07% 308
2014
Q3 		$286M Buy
5,329,038
+690,557
+15% +$36.6M 0.06% 344
2014
Q2 		$243M Buy
+4,638,481
New +$237M 0.05% 391
2013
Q3 		– Sell
-404,700
Closed -$15.9M – 2470
2013
Q2 		$15.9M Buy
+404,700
New +$15.8M ﹤0.01% 1137

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's TEVA Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Teva Pharmaceuticals (TEVA) stake by 59% in Q1 2026, selling an estimated $29.8M and leaving 634,136 shares worth $19.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1052.

T. Rowe Price Associates first reported a position in TEVA in Q2 2013 and has held it in 47 quarters since. The position peaked at $462M in Q1 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • T. Rowe Price Associates held 634,136 shares of Teva Pharmaceuticals worth $19.1M as of Q1 2026.
  • T. Rowe Price Associates sold 925,466 Teva Pharmaceuticals shares in Q1 2026, an estimated $29.8M.
  • Teva Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1052 holding.
  • T. Rowe Price Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • T. Rowe Price Associates's Teva Pharmaceuticals position peaked at $462M in Q1 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.